Mizuho analyst Ann Hynes raised the firm’s price target on McKesson to $376 from $345 and keeps a Neutral rating on the shares post the Q3 results. The recovery in core business volumes remains a tailwind for the drug distributors, Hynes tells investors in a research note.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on MCK:
- CAH vs. MCK: These Healthcare Stocks are Hot and Can Stay Hot
- McKesson price target raised to $416 from $384 at Cowen
- McKesson price target raised to $415 from $375 at Barclays
- McKesson price target raised to $440 from $405 at Baird
- McKesson boosts FY23 adjusted EPS view to $24.45-$24.95 from $23.95-$24.65
